Tokito T, Kolesnik O, Sorensen J, Artac M, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study. BMC Cancer 2024;23.
PMID: 39054476